ABSTRACT
Prevention and treatment of dyslipidemia should therefore be considered as an integral part of individual cardiovascular prevention interventions, which should be addressed primarily to those at higher risk who will benefit most. Statins are the most commonly used options for the pharmacologic treatment of dyslipidemia. In recent decades, numerous clinical trials have demonstrated the efficacy of these drugs to reduce cardiovascular mortality and major non-fatal atherothrombotic events in heterogeneous populations through both primary and secondary prevention. This group of drugs is part of the recommendations of both US and European guidelines, and should be prescribed to all patients who have already had a cardiovascular event and have no specific contraindication. However, a large percentage of patients that would benefit from a statin treatment do not receive them, have been prescribed a low dose or for a limited time. (AU)
Subject(s)
Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic useABSTRACT
La historia del desarrollo de la cirugía como tratamiento de la CCA se inicia desde el nacimiento del presente siglo con los primeros métodos de denervación para eliminar el dolor anginoso. La experimentación sucesiva, acuciosa y crítica, aunada al desarrollo de otras ramas de la ciencia, ha permitido que en la actualidad la cirugía coronaria sea considerada como un método útil y efectivo en el tratamiento de la enfermedad isquémica del miocardio
Subject(s)
Humans , History, 20th Century , Thoracic Surgery/historyABSTRACT
En este artículo de revisión se exponen los planteamientos del uso e indicaciones actuales de las pruebas de cardiología nuclear. Siendo un método incruento, por la fidelidad de sus resultados y fácil reproducibilidad ha ganado un amplio prestigio en el campo de la investigación clínica. Se revisan los procedimientos y sus resultados